litlas
ログインアカウント作成

Dong‐Wan Kim

1990–2026 年に発表

別表記
Dong-Wan Kim · Dong-wan Kim · Dong Wan Kim
249
論文数
62,059
被引用数
101
h 指数
225
i10 指数

被引用数

Dong‐Wan Kim の年別被引用数1971 年: 被引用 1 件1991 年: 被引用 1 件1992 年: 被引用 1 件1993 年: 被引用 1 件1994 年: 被引用 5 件1995 年: 被引用 2 件1996 年: 被引用 4 件1997 年: 被引用 4 件1998 年: 被引用 5 件1999 年: 被引用 4 件2000 年: 被引用 9 件2001 年: 被引用 6 件2002 年: 被引用 7 件2003 年: 被引用 7 件2004 年: 被引用 7 件2005 年: 被引用 52 件2006 年: 被引用 91 件2007 年: 被引用 101 件2008 年: 被引用 118 件2009 年: 被引用 123 件2010 年: 被引用 115 件2011 年: 被引用 98 件2012 年: 被引用 112 件2013 年: 被引用 195 件2014 年: 被引用 273 件2015 年: 被引用 491 件2016 年: 被引用 667 件2017 年: 被引用 822 件2018 年: 被引用 965 件2019 年: 被引用 2,754 件2020 年: 被引用 2,864 件2021 年: 被引用 2,786 件2022 年: 被引用 2,210 件2023 年: 被引用 1,646 件2024 年: 被引用 2,600 件2025 年: 被引用 1,309 件2026 年: 被引用 36 件1972〜1990 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 5,063 件、この内訳の 22.3%中国: 引用元論文 3,567 件、この内訳の 15.7%日本: 引用元論文 1,320 件、この内訳の 5.8%イタリア: 引用元論文 1,242 件、この内訳の 5.5%フランス: 引用元論文 1,048 件、この内訳の 4.6%イギリス: 引用元論文 1,029 件、この内訳の 4.5%韓国: 引用元論文 941 件、この内訳の 4.1%ドイツ: 引用元論文 883 件、この内訳の 3.9%スペイン: 引用元論文 845 件、この内訳の 3.7%カナダ: 引用元論文 665 件、この内訳の 2.9%オランダ: 引用元論文 532 件、この内訳の 2.4%オーストラリア: 引用元論文 498 件、この内訳の 2.2%
0%22.3%その他 22.4%

機関

分野

  • Medicine74%
  • Biochemistry, Genetics and Molecular Biology13.8%
  • Immunology and Microbiology4.1%
  • Materials Science2.3%
  • Engineering2%
  • Chemistry0.8%
  • その他3%

トピック

  • Lung Cancer Treatments and Mutations13.5%
  • Cancer Immunotherapy and Biomarkers10.1%
  • Lung Cancer Research Studies7.3%
  • Lung Cancer Diagnosis and Treatment4.4%
  • Cancer Genomics and Diagnostics3.4%
  • Colorectal Cancer Treatments and Studies1.9%
  • その他59.4%

共著者

全論文

検索で開く
  1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

    著者: Roy S. Herbst, Paul Baas, Dong‐Wan Kim, Enriqueta Felip, José Luis Perez‐Gracia, Ji‐Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M. Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled‐Filhart, Edward B. Garon - The Lancet 2015 被引用: 6,537

  2. AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

    著者: Darren A.E. Cross, Susan Ashton, Serban Ghiorghiu, Cath Eberlein, Caroline A. Nebhan, Paula J. Spitzler, Jonathon P. Orme, M. Raymond V. Finlay, Richard A. Ward, Martine J. Mellor, Gareth Hughes, Amar Rahi, Vivien N. Jacobs, Monica Red Brewer, Eiki Ichihara, Jing Sun, Hailing Jin, Peter Ballard, Katherine Al-Kadhimi, Rachel Rowlinson, Teresa Klinowska, Graham H.P. Richmond, Mireille Cantarini, Dong‐Wan Kim, Malcolm Ranson, William Pao - Cancer Discovery 2014 被引用: 2,225

  3. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

    著者: Solange Peters, D. Ross Camidge, Alice T. Shaw, Shirish M. Gadgeel, Jin Seok Ahn, Dong‐Wan Kim, Sai‐Hong Ignatius Ou, M. Pérol, Rafał Dziadziuszko, Rafael Rosell, Ali Zeaiter, Emmanuel Mitry, Sophie Golding, Bogdana Balas, Johannes Noé, Peter N. Morcos, Tony Mok - New England Journal of Medicine 2017 被引用: 2,455

  4. First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer

    著者: Alice T. Shaw, Todd M. Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazières, Dong‐Wan Kim, Tony Mok, Anna Polli, Holger Thurm, Anna Maria Calella, Gerson Peltz, Benjamin Solomon - New England Journal of Medicine 2020 被引用: 1,064

  5. Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

    著者: Keunchil Park, Eric B. Haura, Natasha B. Leighl, Paul Mitchell, Catherine A. Shu, Nicolas Girard, Santiago Viteri, Ji‐Youn Han, Sang‐We Kim, Chee Khoon Lee, Joshua K. Sabari, Alexander I. Spira, Tsung‐Ying Yang, Dong‐Wan Kim, Ki Hyeong Lee, Rachel E. Sanborn, José Trigo, Kōichi Goto, Jong‐Seok Lee, James Chih‐Hsin Yang, Ramaswamy Govindan, Joshua Bauml, Pilar Garrido, Matthew Krebs, Karen L. Reckamp, John Xie, Joshua C. Curtin, Nahor Haddish‐Berhane, Amy Roshak, Dawn Millington, Patricia Lorenzini, Meena Thayu, Roland E. Knoblauch, Byoung Chul Cho - Journal of Clinical Oncology 2021 被引用: 632

  6. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

    著者: Benjamin Solomon, Tony Mok, Dong‐Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Shrividya Iyer, Arlene Reisman, Keith D. Wilner, Jennifer Tursi, Fiona Blackhall - New England Journal of Medicine 2014 被引用: 3,213

  7. Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

    著者: Kōichi Goto, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang‐We Kim, David Planchard, Myung‐Ju Ahn, Egbert F. Smit, Adrianus J. de Langen, M. Pérol, Elvire Pons‐Tostivint, Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, Dong‐Wan Kim, Chih‐Hsi S. Kuo, James Chih‐Hsin Yang, Kaline Pereira, Fu-Chih Cheng, Ayumi Taguchi, Yingkai Cheng, Wenqin Feng, Zenta Tsuchihashi, Pasi A. Jänne - Journal of Clinical Oncology 2023 被引用: 299

  8. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

    著者: Helena A. Yu, Yasushi Goto, Hidetoshi Hayashi, Enriqueta Felip, James Chih‐Hsin Yang, Martin Reck, Kiyotaka Yoh, Se‐Hoon Lee, Luis Paz‐Ares, Benjamin Besse, Paolo Bironzo, Dong‐Wan Kim, Melissa L. Johnson, Yi‐Long Wu, Thomas John, Steven Kao, Toshiyuki Kozuki, Erminia Massarelli, Jyoti D. Patel, Egbert F. Smit, Karen L. Reckamp, Qian Dong, Pomy Shrestha, Pang‐Dian Fan, Parul Patel, Andrea Sporchia, David Sternberg, Dalila Sellami, Pasi A. Jänne - Journal of Clinical Oncology 2023 被引用: 225

  9. Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer

    著者: D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn, James Chih‐Hsin Yang, Ji‐Youn Han, Jong Seok Lee, Maximilian J. Hochmair, Jacky Yu-Chung Li, Gee‐Chen Chang, Ki Hyeong Lee, Cesare Gridelli, Angelo Delmonte, Rosario García Campelo, Dong‐Wan Kim, Alessandra Bearz, Frank Griesinger, Alessandro Morabito, Enriqueta Felip, Raffaele Califano, Sharmistha Ghosh, Alexander I. Spira, Scott Gettinger, Marcello Tiseo, Neeraj Gupta, J. Haney, David Kerstein, Sanjay Popat - New England Journal of Medicine 2018 被引用: 976

  10. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

    著者: Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim, David Planchard, Yuichiro Ohe, Suresh S. Ramalingam, Myung‐Ju Ahn, Sang-We Kim, Wu‐Chou Su, Leora Horn, Daniel Haggstrom, Enriqueta Felip, Joo-Hang Kim, Paul Frewer, Mireille Cantarini, Kathryn H. Brown, Paul A. Dickinson, Serban Ghiorghiu, Malcolm Ranson - New England Journal of Medicine 2015 被引用: 2,111

  11. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

    著者: Justin F. Gainor, Giuseppe Curigliano, Dong‐Wan Kim, Ki Hyeong Lee, Benjamin Besse, Christina S. Baik, Robert C. Doebele, Philippe A. Cassier, Gilberto Lopes, Daniel S.W. Tan, Elena Garralda, Luis Paz‐Ares, Byoung Chul Cho, Shirish M. Gadgeel, Michael Thomas, Stephen V. Liu, Matthew H. Taylor, Aaron S. Mansfield, Viola W. Zhu, Corinne Clifford, Hui Zhang, Michael Palmer, Jennifer Green, Christopher D. Turner, Vivek Subbiah - The Lancet Oncology 2021 被引用: 443

  12. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR -Mutated Non–Small Cell Lung Cancer

    著者: Pasi A. Jänne, Christina Baik, Wu-Chou Su, Melissa L. Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong-Wan Kim, Marianna Koczywas, Kathryn A. Gold, Conor E. Steuer, Haruyasu Murakami, James Chih-Hsin Yang, Sang-We Kim, Michele Vigliotti, Rong Shi, Zhenhao Qi, Yang Qiu, Lihui Zhao, David Sternberg, Channing Yu, Helena A. Yu - Cancer Discovery 2021 被引用: 287

  13. Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

    著者: Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne - New England Journal of Medicine 2013 被引用: 3,406

  14. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

    著者: Benjamin Solomon, Todd M. Bauer, Tony Mok, Geoffrey Liu, Julien Mazières, Filippo de Marinis, Yasushi Goto, Dong‐Wan Kim, Yi‐Long Wu, Jacek Jassem, Froylán López López, Ross A. Soo, Alice T. Shaw, Anna Polli, Rossella Messina, Laura Iadeluca, Francesca Toffalorio, Enriqueta Felip - The Lancet Respiratory Medicine 2022 被引用: 221

  15. Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

    著者: D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn, James Chih‐Hsin Yang, Ji‐Youn Han, Maximilian J. Hochmair, Ki Hyeong Lee, Angelo Delmonte, M.R. García Campelo, Dong‐Wan Kim, Frank Griesinger, Enriqueta Felip, Raffaele Califano, Alexander I. Spira, Scott Gettinger, Marcello Tiseo, Huamao Mark Lin, Yuyin Liu, Florin Vranceanu, Huifeng Niu, Pingkuan Zhang, Sanjay Popat - Journal of Thoracic Oncology 2021 被引用: 372

  16. Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

    著者: Benjamin Solomon, Geoffrey Liu, Enriqueta Felip, Tony Mok, Ross A. Soo, Julien Mazières, Alice T. Shaw, Filippo de Marinis, Yasushi Goto, Yi‐Long Wu, Dong‐Wan Kim, Jean-François Martini, Rossella Messina, Jolanda Paolini, Anna Polli, Despina Thomaidou, Francesca Toffalorio, Todd M. Bauer - Journal of Clinical Oncology 2024 被引用: 313

  17. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

    著者: Alexander Drilon, Sai‐Hong Ignatius Ou, Byoung Chul Cho, Dong‐Wan Kim, Jeeyun Lee, Jessica J. Lin, Viola W. Zhu, Myung‐Ju Ahn, D. Ross Camidge, Judy Nguyen, Dayong Zhai, Wei Deng, Zhongdong Huang, Evan Rogers, Juliet Liu, Jeff Whitten, John K. C. Lim, Shanna Stopatschinskaja, David M. Hyman, Robert C. Doebele, J. Jean Cui, Alice T. Shaw - Cancer Discovery 2018 被引用: 480

  18. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

    著者: Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne, Li Zhang, Michael Boyer, Tony Mok, Vera Hirsh, James Chih‐Hsin Yang, Ki Hyeong Lee, Shun Lü, Yuankai Shi, Sang-We Kim, Janessa Laskin, Dong‐Wan Kim, Catherine Dubos Arvis, Karl Kölbeck, Scott A. Laurie, Chun-Ming Tsai, Mehdi Shahidi, Miyoung Kim, Dan Massey, Victoria Zazulina, Luis Paz‐Ares - The Lancet Oncology 2016 被引用: 1,175

  19. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

    著者: Grace K. Dy, Ramaswamy Govindan, Vamsidhar Velcheti, Gerald S. Falchook, Antoîne Italiano, Jürgen Wolf, Adrian G. Sacher, Toshiaki Takahashi, Suresh S. Ramalingam, Christophe Dooms, Dong‐Wan Kim, Alfredo Addeo, Jayesh Desai, Martin Schüler, Pascale Tomasini, David S. Hong, Piro Lito, Qui Tran, Simon Jones, Abraham Anderson, Antreas Hindoyan, Wendy Snyder, Ferdinandos Skoulidis, Bob T. Li - Journal of Clinical Oncology 2023 被引用: 149

  20. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas

    著者: Jake June-Koo Lee, Junehawk Lee, Sehui Kim, Soyeon Kim, Jeonghwan Youk, Seongyeol Park, Yohan An, Bhumsuk Keam, Dong‐Wan Kim, Dae Seog Heo, Young Tae Kim, Jin-Soo Kim, Se Hyun Kim, Jong Seok Lee, Se‐Hoon Lee, Keunchil Park, Ja‐Lok Ku, Yoon Kyung Jeon, Doo Hyun Chung, Peter J. Park, Joon Kim, Tae‐Min Kim, Young Seok Ju - Journal of Clinical Oncology 2017 被引用: 508

  21. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

    著者: Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim, Byoung Chul Cho, Radj Gervais, José Luis Perez‐Gracia, Ji‐Youn Han, Margarita Majem, Martin Förster, I. Monnet, Silvia Novello, Matthew A. Gubens, Michael Boyer, Wu‐Chou Su, Ayman Samkari, Erin Jensen, Julie Kobie, Bilal Piperdi, Paul Baas - Journal of Thoracic Oncology 2021 被引用: 312

  22. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301

    著者: Byoung Chul Cho, Myung‐Ju Ahn, Jin Hyoung Kang, Ross A. Soo, Thanyanan Reungwetwattana, James Chih‐Hsin Yang, İrfan Çiçin, Dong‐Wan Kim, Yi‐Long Wu, Shun Lü, Ki Hyeong Lee, Yong‐Kek Pang, Anastasia Zimina, Chin Heng Fong, Elena Poddubskaya, Ahmet Sezer, Soon Hin How, Pongwut Danchaivijitr, Yukyung Kim, Yeji Lim, Taewon An, Hana Lee, Hae Mi Byun, Bojan Zarić - Journal of Clinical Oncology 2023 被引用: 137

  23. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

    著者: Winette T.A. van der Graaf, Jean‐Yves Blay, Sant P. Chawla, Dong‐Wan Kim, B. Bui-Nguyen, Paolo G. Casali, Patrick Schöffski, Massimo Aglietta, Arthur P. Staddon, Yasuo Beppu, Axel Le Cesne, Hans Gelderblom, Ian Judson, Nobuhito Araki, M. Ouali, Sandrine Marréaud, Rachel Hodge, Mohammed R Dewji, Corneel Coens, George D. Demetri, Christopher D.�M. Fletcher, Angelo Paolo Dei Tos, Peter Hohenberger - The Lancet 2012 被引用: 2,087

  24. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

    著者: James Chih‐Hsin Yang, Sang-We Kim, Dong‐Wan Kim, Jong Seok Lee, Byoung Chul Cho, Jin-Seok Ahn, Dae H. Lee, Tae Min Kim, Jonathan W. Goldman, Ronald B. Natale, Andy Brown, Barbara Collins, Juliann Chmielecki, Karthick Vishwanathan, Ariadna Mendoza‐Naranjo, Myung‐Ju Ahn - Journal of Clinical Oncology 2019 被引用: 397